Mirion Technologies, Inc. MIR

Technology SIC 3829 - Measuring & Controlling Devices, NEC NAICS Manufacturing › Computer and Electronic Product Manufacturing › Navigational, Measuring, Electromedical, and Control Instruments Manufacturing › Other Measuring and Controlling Device Manufacturing derived NYSE

At Mirion, we deliver vital protection that unlocks the transformative potential of radiation to move science, industry and medicine forward. For more than 60 years Mirion and our predecessor companies have provided products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. As a global leader in the field of radiation safety and innovation, we bring together unrivaled expertise with an unmatched range of reliably precise technologies.

Safety is at the core of what we do. Through critical nuclear facilities, R&D labs, cancer centers, diagnostic imaging facilities, and on the front lines, Mirion empowers innovations that move radiation safety, measurement and medicine further to shape our future world. Many of our markets are characterized by the need to meet rigorous regulatory standards, design qualifications, and operating requirements. Throughout our history, we have successfully leveraged the strength of our expertise to continually drive innovation and expand the commercial applications of our core technology competencies.

Last close 14.81 2026-10-23
Market cap $3.62B estimated share count
52-week range 14.04 - 30.28

Valuation FY2025 figures against the last close

P/S3.9x
P/E134.6x
P/FCF33.9x
EV/EBITDA19.3x
Dividend yield—
Diluted EPS0.11

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Nuclear & Safety
  • Medical
Revenue by segment, 2 categories over 3 years. The same figures are in the table below. FY2025 Nuclear & Safety, FY2025: 614.6M (66.4%) 66% Nuclear & Safety Medical, FY2025: 310.8M (33.6%) 34% Medical FY2024 Nuclear & Safety, FY2024: 561.1M (65.2%) 65% Medical, FY2024: 299.7M (34.8%) 35% FY2023 Nuclear & Safety, FY2023: 516.4M (64.5%) 64% Medical, FY2023: 284.5M (35.5%) 36%
Segment FY2025FY2024FY2023
Nuclear & Safety $614.6M $561.1M $516.4M
Medical $310.8M $299.7M $284.5M

As the company reported it, from the “Segment Information - Schedule of Revenue from External Customers by Geographic Areas (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue $925.4M$860.8M$800.9M$717.8M$611.6M$478.2M$440.1M——
Cost of revenue $486.8M$461.1M$444.5M$407.7M$359.8M$281.2M$251.9M——
Gross profit $438.6M$399.7M$356.4M$310.1M$251.8M$197.0M$188.2M——
R&D $38.9M$35.0M$31.7M$30.3M$29.4M$15.9M$14.0M——
SG&A $348.2M$341.1M$340.1M$362.3M$211.2M$158.1M$145.4M——
Total operating expenses $387.1M$374.9M$378.3M$607.9M$240.6M$174.0M$159.4M——
Operating income $51.5M$24.8M-$21.9M-$297.8M$11.2M$23.0M$28.8M——
Interest expense $42.2M$57.9M$61.9M——————
Pre-tax income $32.7M-$33.9M-$105.3M-$306.6M-$164.3M-$124.6M-$126.2M——
Income tax $2.9M$2.7M$6.6M$18.2M$5.9M$5.5M$4.2M——
Net income $28.8M-$36.1M-$96.9M-$276.9M-$158.3M-$119.1M-$122.0M-$295—
EPS, basic 0.13-0.18-0.49-1.53-24.18-18.45-19.36——
EPS, diluted 0.11-0.18-0.49-1.53-24.18-18.45-19.36——
Shares, diluted (wtd. avg.) 261.2M205.0M196.4M181.1M6.5M6.5M6.3M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents $412.3M$175.2M$128.8M$75.0M$85.3M$120.0M$37.6M$35.9M$0
Receivables $181.6M$177.7M$172.3M$171.2M$133.3M$97.3M———
Inventory $152.6M$133.2M$144.1M$143.3M$113.2M$90.2M———
Total current assets $893.7M$594.7M$538.6M$480.6M$433.9M$389.7M$5.0K——
Property, plant and equipment $154.9M$146.3M$134.5M$124.3M$88.8M$75.2M———
Goodwill $1.87B$1.43B$1.45B$1.42B$1.66B$522.6M$511.6M——
Other intangibles $606.3M$411.6M$538.8M$650.4M$326.3M$248.3M———
Total assets $3.59B$2.64B$2.72B$2.74B$1.55B$1.24B$5.0K——
Accounts payable $57.4M$56.5M$58.7M$67.7M$47.1M$38.7M$636——
Short-term debt $1.6M$1.2M$1.2M$5.3M$6.4M$41.1M———
Total current liabilities $316.1M$263.4M$265.7M$244.3M$188.2M$183.5M$636——
Long-term debt $443.1M$685.2M$684.7M$801.5M$885.7M$669.8M———
Total liabilities $1.67B$1.08B$1.17B$1.27B$2.39B$1.96B$636——
Retained earnings -$512.7M-$541.5M-$505.4M-$408.5M-$888.0M-$729.7M-$636——
Total equity $1.87B$1.51B$1.55B$1.47B$1.78B-$716.5M-$587.7M-$448.8M$0

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Operating cash flow $143.3M$99.1M$95.2M$39.4M$53.6M$39.5M$14.7M$0—
Depreciation and amortisation $138.1M$150.4M$162.8M$174.5M$83.6M$68.4M———
Stock-based compensation $15.2M$15.6M$21.9M$31.8M$0$200.0K$100.0K——
Capital expenditure $36.4M$48.8M$37.1M$34.2M$23.2M$19.9M$16.5M——
Investing cash flow -$694.6M-$43.7M-$64.7M-$39.5M-$313.3M-$75.6M-$25.6M——
Financing cash flow $775.9M-$3.3M$22.6M-$7.0M$239.0M$118.9M$15.0M$5.0K—
Buybacks $49.6M$0$0$0$0————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-009869.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B Net income, FY2018: -295 Revenue, FY2019: 440.1M Gross profit, FY2019: 188.2M Net income, FY2019: -122M Revenue, FY2020: 478.2M Gross profit, FY2020: 197M Net income, FY2020: -119.1M Revenue, FY2021: 611.6M Gross profit, FY2021: 251.8M Net income, FY2021: -158.3M Revenue, FY2022: 717.8M Gross profit, FY2022: 310.1M Net income, FY2022: -276.9M Revenue, FY2023: 800.9M Gross profit, FY2023: 356.4M Net income, FY2023: -96.9M Revenue, FY2024: 860.8M Gross profit, FY2024: 399.7M Net income, FY2024: -36.1M Revenue, FY2025: 925.4M Gross profit, FY2025: 438.6M Net income, FY2025: 28.8M FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — $440.1M $478.2M $611.6M $717.8M $800.9M $860.8M $925.4M
Gross profit — — $188.2M $197.0M $251.8M $310.1M $356.4M $399.7M $438.6M
Net income — -$295 -$122.0M -$119.1M -$158.3M -$276.9M -$96.9M -$36.1M $28.8M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3829

TickerCompanyMarket capP/ERevenue growth
TMO THERMO FISHER SCIENTIFIC INC. $249.14B 38.0x 3.9%
ROK ROCKWELL AUTOMATION, INC $47.32B 55.6x 0.9%
TRMB TRIMBLE INC. $14.80B 36.1x -2.6%
ONTO ONTO INNOVATION INC. $9.75B 71.5x 1.8%
QSI Quantum-Si Inc $304.9M — -20.3%
OWLT Owlet, Inc. $119.8M — 35.4%
GEOS GEOSPACE TECHNOLOGIES CORP $55.1M — -18.3%
BCHT Birchtech Corp. $29.7M — 1.3%